psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
Company profile
Ticker
EYPT
Exchange
Website
CEO
Nancy Sue Lurker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
pSivida Corp., pSivida LTD
SEC CIK
Corporate docs
Subsidiaries
EyePoint Pharmaceuticals US, Inc. • pSiMedica Limited • EyePoint Pharmaceuticals Securities Corporation • Icon Bioscience, Inc. ...
IRS number
262774444
EYPT stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
8 May 24
8-K
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
6 May 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
8-K
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
4 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Dec 23
Transcripts
EYPT
Earnings call transcript
2023 Q4
7 Mar 24
EYPT
Earnings call transcript
2023 Q3
1 Nov 23
EYPT
Earnings call transcript
2023 Q2
2 Aug 23
EYPT
Earnings call transcript
2023 Q2
2 Aug 23
EYPT
Earnings call transcript
2023 Q1
3 May 23
EYPT
Earnings call transcript
2022 Q4
2 Mar 23
EYPT
Earnings call transcript
2022 Q3
2 Nov 22
EYPT
Earnings call transcript
2022 Q2
3 Aug 22
EYPT
Earnings call transcript
2022 Q1
4 May 22
EYPT
Earnings call transcript
2021 Q4
3 Mar 22
Latest ownership filings
4
Bihua Chen
8 May 24
SC 13G/A
Adage Capital Management, L.P.
1 May 24
SC 13G
Adage Capital Management, L.P.
30 Apr 24
3
Robert Atchinson
22 Apr 24
4
Bihua Chen
22 Apr 24
4
Dario A. Paggiarino
2 Apr 24
4
Ramiro Ribeiro
4 Mar 24
3
Ramiro Ribeiro
4 Mar 24
4
Jay S. Duker
28 Feb 24
4
Jay S. Duker
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm |
Cash burn (monthly) | 2.19 mm | (no burn) | 4.80 mm | 8.54 mm | 5.07 mm | (no burn) |
Cash used (since last report) | 16.34 mm | n/a | 35.86 mm | 63.78 mm | 37.86 mm | n/a |
Cash remaining | 116.84 mm | n/a | 97.33 mm | 69.40 mm | 95.32 mm | n/a |
Runway (months of cash) | 53.4 | n/a | 20.3 | 8.1 | 18.8 | n/a |
Institutional ownership, Q4 2023
22.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 4 |
Closed positions | 98 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.08 bn |
Total shares | 11.47 mm |
Total puts | 100.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Cormorant Asset Management | 6.04 mm | $110.74 mm |
Therapeutics OcuMension | 3.01 mm | $19.81 mm |
EW Healthcare Partners | 2.34 mm | $42.88 mm |
DekaBank Deutsche Girozentrale | 35.00 k | $820.00 k |
WSFL Woodstock | 22.25 k | $514.27 mm |
Mirae Asset Global Investments | 15.58 k | $360.15 mm |
China Universal Asset Management | 4.09 k | $94.00 k |
FNY Investment Advisers | 1.21 k | $27.00 k |
Cutler | 1.10 k | $25.00 k |
Cedar Mountain Advisors | 1.00 k | $23.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 12.36 | 207,153 | 2.56 mm | 8,325,000 |
6 May 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 11.7 | 642,847 | 7.52 mm | 8,117,847 |
18 Apr 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 18.9 | 186,521 | 3.53 mm | 7,475,000 |
18 Apr 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 17.62 | 395,244 | 6.96 mm | 7,288,479 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 7,096 | 146.67 k | 67,080 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 2,957 | 61.12 k | 74,176 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 15,493 | 320.24 k | 77,133 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,000 | 0.00 | 92,626 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 30,570 | 0.00 | 78,626 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,834 | 0.00 | 48,056 |
News
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
13 May 24
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $30
13 May 24
Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38
8 May 24
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
8 May 24
Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)
7 May 24
Press releases
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
2 Apr 24
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
27 Feb 24
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 Feb 24